Vlaams Instituut voor Biotechnologie

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023
Science, Research, General Health, Health, Health Technology, Technology, Genetics, Semiconductor, Cloud, Molecule, Society, Protein, Arginine, Protein sequencing, Senior, PIN, VIB, Proteomics, HUPO, Acquisition, Platinum, Flemish, Disease, American Society of Human Genetics, IAB, Partnership, GAAP, Quantum, ASHG, Human Proteome Organization, Rationalization, EBITDA, Investment, Human genetics, Drug development, Conference, Biovista, Proteome, Dicarboxylic acid, Vlaams Instituut voor Biotechnologie, Cryptocurrency, Fine chemical, Management, Microscope, Pharmaceutical industry, Arms industry, Video game, Neuroscience

Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.

Key Points: 
  • Selling, general and administrative expenses were $11.2 million in the fourth quarter of 2022, compared to $13.4 million in the fourth quarter of 2021.
  • Net loss was $33.1 million in the fourth quarter of 2022, compared to a net loss of $29.4 million in the fourth quarter of 2021.
  • Adjusted EBITDA was negative $24.5 million in the fourth quarter of 2022, compared to negative $20.4 million in the fourth quarter of 2021.
  • Quantum-Si will host a conference call to discuss its fourth quarter and fiscal year 2022 financial results on Monday, March 6, 2023, at 8:30 AM Eastern Time (ET).

Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow

Retrieved on: 
Monday, October 24, 2022
Oncology, Health, Neurology, Research, Science, Biotechnology, Infection, Novo Nordisk Foundation Center for Protein Research, Disease, Vlaams Instituut voor Biotechnologie, German Cancer Research Center, Agriculture, Workflow, Laboratory, IT University of Copenhagen, Monheim am Rhein, Neuroscience, List of life sciences, DKFZ, Developmental biology, Investment, Partnership, Technology, University, Doctor of Philosophy, Cartography, Health, Neurology, Board, CEO, VIB, Resolve, DNA, COVID-19, Pathology, View, Medical imaging, Microscope, Genetics

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.
  • Resolve intends to build on its successful commercial launch and use the proceeds from the financing to rapidly scale operations and accelerate product development to meet growing demand worldwide.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow

Retrieved on: 
Tuesday, June 7, 2022
Research, Infectious Diseases, Genetics, Biotechnology, Health, Agriculture, Natural Resources, Science, Oncology, Other Science, Inflammation Research, Â, Biomarker, Macrophage, Infection, German Resource Center for Genome Research, Doctor of Philosophy, Stanford University School of Medicine, Inflammation, Multimedia, Neurology, Technology, German Cancer Research Center, Research, Vlaams Instituut voor Biotechnologie, Gold, Tissue, View, Novo Nordisk Foundation Center for Protein Research, Observation, Agriculture, Lunch, Personalized medicine, CEO, List of life sciences, Center, Monheim am Rhein, B cell, Laboratory, Mouse, Molecular medicine, University of Copenhagen Nano-Science Center, Neuroscience, Cell, Liver, University, Patient, DNA, Steatosis, Science, Cartography, Disease, Fatty liver disease, VIB, Developmental biology, Pleasure, Systems biology, DKFZ, Medical imaging, Pharmaceutical industry, Microscope, Genetics, Genomics

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.
  • Previously, these customers accessed the power of the system through the companys commercial Molecular Cartography service offering and early access program.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

First Center of Excellence on Dynamic Single-Molecule Studies for Brain and Disease Research established in Belgium

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Frederic Rousseau, Joost Schymkowitz, Flanders, VIB, Neurodegeneration, Vlaams Instituut voor Biotechnologie, Switch Laboratory

The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.

Key Points: 
  • The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.
  • Together, they form the first Centre of Excellence on Dynamic Single-Molecule Analysis for Brain and Disease Research in Belgium.
  • Frederic Rousseau & Joost Schymkowitz, group leaders of the Switch lab at the VIB-KU Leuven Center for Brain & Disease Research, study the relevance of protein folding in various neurodegenerative conditions.
  • VIB is highly committed to being the driving force behind the growth of the dynamic life sciences cluster in Flanders.

First Center of Excellence on Dynamic Single-Molecule Studies for Brain and Disease Research established in Belgium

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Frederic Rousseau, Joost Schymkowitz, Flanders, VIB, Neurodegeneration, Vlaams Instituut voor Biotechnologie, Switch Laboratory

The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.

Key Points: 
  • The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.
  • Together, they form the first Centre of Excellence on Dynamic Single-Molecule Analysis for Brain and Disease Research in Belgium.
  • Frederic Rousseau & Joost Schymkowitz, group leaders of the Switch lab at the VIB-KU Leuven Center for Brain & Disease Research, study the relevance of protein folding in various neurodegenerative conditions.
  • VIB is highly committed to being the driving force behind the growth of the dynamic life sciences cluster in Flanders.

ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting

Retrieved on: 
Friday, April 9, 2021
Flanders, Organizations, Europe, Science and technology in Belgium, Vrije, Education in Belgium, Vlaams Instituut voor Biotechnologie

The second presentation is an e-poster presentation of preclinical data:

Key Points: 
  • The second presentation is an e-poster presentation of preclinical data:
    Authors: Heleen Roose, Elizabeth Allen, Helena Van Damme, Bruno Dombrecht, Rosa Martn-Prez, Damya Laoui, Jo A.
  • Oncurious NV, Leuven, Belgium, Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel and Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium, VIB Discovery Sciences, Leuven-Ghent, Belgium.
  • Date and Time: The e-poster will be available on AACRs website on Saturday 10th April at 8:30 AM US EDT (the first day of the virtual AACR Annual Meeting).
  • The e-poster will remain available for viewing through to Monday 21st June 2021.

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

Retrieved on: 
Wednesday, June 3, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Flanders, Organizations, Biology, Science, Science and technology in Belgium, VIB, Vrije Universiteit Brussel, Vlaams Instituut voor Biotechnologie, Joost Schymkowitz, Lode Wyns

Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective June 1, 2020.

Key Points: 
  • Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective June 1, 2020.
  • With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini joins Confo from his most recent position as Vice President, Development Sciences at Kymab.
  • Commenting on the appointment, Cedric Ververken, CEO of Confo Therapeutics said: Confo is focused on strategically expanding and shaping the Company to facilitate the rapid advancement of our first drug candidates.
  • Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and Vlaams Instituut voor Biotechnologie (VIB) in 2015.

Inari Broadens Research Footprint With Expansion to Belgian Life Sciences Hub

Retrieved on: 
Wednesday, February 6, 2019
Deities, Flanders, VIB, Inari Ōkami, Flemish people, Science and technology in Belgium, Vlaams Instituut voor Biotechnologie

The launch represents the company's first expansion outside of the United States and provides Inari access to advanced resources and talent in one of the world's premier hubs for plant research.

Key Points: 
  • The launch represents the company's first expansion outside of the United States and provides Inari access to advanced resources and talent in one of the world's premier hubs for plant research.
  • Inari has partnered with VIB, the renowned life sciences research institute, and ILVO, the institute for agriculture, fisheries and food in Flanders.
  • Inari's 550-square-meter laboratory and office facility is located at BioScape, a leading life sciences incubator adjacent to VIB.
  • VIB is a life sciences research institute in Flanders, Belgium.